Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
A 52-week, open-label extension study to evaluate the safety and tolerability of licarbazepine 750- 2000 mg/day in the treatment of manic episodes of bipolar I disorder
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. written informed consent provided prior to participation in the extension study
2. successful completion of study CLIC477D2301
3. willingness and ability to comply with all study requirements
You may not be if
1. premature discontinuation from study CLIC477D2301
2. failure to comply with the study CLIC477D2301 protocol
Clareo Health | An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
